Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | DRD3 | P35462 | 1/20 | 0.76 |
| ▸ | CASR | P41180 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24406703 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL3881700 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL5471668 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL9633453 | 0.98 | KMT2A (0.77) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL9633690 | 0.98 | KMT2A (0.77) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL11094399 | 0.91 | MTOR (0.75) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL1101513 | 0.91 | CYP3A4 (0.70) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL5461331 | 0.91 | CYP3A4 (0.70) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL10779809 | 0.91 | CYP3A4 (0.70) | CYP3A4LMNACHRM2HTR1AADRA2A | |
| SCHEMBL12964248 | 0.89 | CYP3A4 (0.68) | CYP3A4LMNACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0577171-A2 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-05 | — | — | EP | claimed |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF (US) | 2019-01-31 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
| EP-1483273-B1 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | BERENS ULRICH | 2006-10-26 | — | — | US | disclosed |
| US-7094907-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20040260091-A1 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2004-12-23 | — | — | US | disclosed |
| EP-1483273-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | Solvias AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| US-6573395-B2 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | FIRMENICH SA (CH) | 2003-06-03 | — | — | US | disclosed |
| WO-2003031456-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| EP-1012131-B1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH & CIE (CH) | 2003-03-19 | — | — | EP | disclosed |
| US-20020161252-A1 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | FIRMENICH SA, A SWISS COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-6392103-B1 | USING ORGANOMETALLIC COMPOUND AS CATALYST | FIRMENICH SA (CH) | 2002-05-21 | — | — | US | disclosed |
| EP-1012131-A1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH SA (CH) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999012877-A1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH S.A. (CH) | 1999-03-18 | — | — | WO | disclosed |
| WO-1991007967-A2 | METHOD OF PREVENTING OR LIMITING REPERFUSION DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-13 | — | — | WO | disclosed |
| US-4204997-A | Asymmetric amination of 1,3-dienes | MONSANTO COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | CYP3A4 3167/4885LMNA 2248/4885CHRM2 3936/4885 |
| US-20020161252-A1 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | ERH, POLH, PNMT | CYP3A4 1202/4885LMNA 1045/4885CHRM2 1849/4885 |
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | NR2E3, WNK2, OXSR1 | CYP3A4 1948/4885LMNA 3394/4885CHRM2 20/4885 |
| US-20040260091-A1 | Ligands for asymmetric reactions | COASY, ICMT, AP2M1 | CYP3A4 72/4885LMNA 4664/4885CHRM2 1607/4885 |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | CYP3A4 3167/4885LMNA 2248/4885CHRM2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.